Clarus Lifesciences Iii, L.p. - Net Worth and Insider Trading

Clarus Lifesciences Iii, L.p. Net Worth

The estimated net worth of Clarus Lifesciences Iii, L.p. is at least $607 Million dollars as of 2024-06-02. Clarus Lifesciences Iii, L.p. is the 10% Owner of Forty Seven Inc and owns about 4,755,440 shares of Forty Seven Inc (FTSV) stock worth over $454 Million. Clarus Lifesciences Iii, L.p. is the 10% Owner of Imago BioSciences Inc and owns about 3,375,037 shares of Imago BioSciences Inc (IMGO) stock worth over $122 Million. Clarus Lifesciences Iii, L.p. is also the 10% Owner of Annexon Inc and owns about 2,730,635 shares of Annexon Inc (ANNX) stock worth over $13 Million. Besides these, Clarus Lifesciences Iii, L.p. also holds CalciMedica Inc (CALC) , Entasis Therapeutics Holdings Inc (ETTX) , Gritstone Bio Inc (GRTS) , Talaris Therapeutics Inc (TALS) . Details can be seen in Clarus Lifesciences Iii, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Clarus Lifesciences Iii, L.p. has not made any transactions after 2021-07-20 and currently still holds the listed stock(s).

Transaction Summary of Clarus Lifesciences Iii, L.p.

Clarus Lifesciences Iii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Clarus Lifesciences Iii, L.p. owns 10 companies in total, including Praxis Precision Medicines Inc (PRAX) , ESSA Pharma Inc (EPIX) , and CalciMedica Inc (CALC) among others .

Click here to see the complete history of Clarus Lifesciences Iii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Clarus Lifesciences Iii, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
PRAX	Praxis Precision Medicines Inc	2020-10-15	10 percent owner
EPIX	ESSA Pharma Inc	2020-10-01	10 percent owner
CALC	CalciMedica Inc	2020-09-29	10 percent owner
		2020-07-28	10 percent owner
		2018-06-20	10 percent owner
		2018-09-28	10 percent owner
		2018-09-28	10 percent owner
		2018-07-02	10 percent owner
		2022-03-30	10 percent owner
		2021-05-11	10 percent owner

Clarus Lifesciences Iii, L.p. Latest Holdings Summary

Clarus Lifesciences Iii, L.p. currently owns a total of 7 stocks. Among these stocks, Clarus Lifesciences Iii, L.p. owns 4,755,440 shares of Forty Seven Inc (FTSV) as of July 2, 2018, with a value of $454 Million and a weighting of 74.85%. Clarus Lifesciences Iii, L.p. owns 3,375,037 shares of Imago BioSciences Inc (IMGO) as of July 20, 2021, with a value of $122 Million and a weighting of 20.03%. Clarus Lifesciences Iii, L.p. also owns 2,730,635 shares of Annexon Inc (ANNX) as of July 28, 2020, with a value of $13 Million and a weighting of 2.17%. The other 4 stocks CalciMedica Inc (CALC) , Entasis Therapeutics Holdings Inc (ETTX) , Gritstone Bio Inc (GRTS) , Talaris Therapeutics Inc (TALS) have a combined weighting of 2.95% among all his current holdings.

Latest Holdings of Clarus Lifesciences Iii, L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
FTSV	Forty Seven Inc	2018-07-02	4,755,440	95.51	454,192,074
IMGO	Imago BioSciences Inc	2021-07-20	3,375,037	36.01	121,535,082
ANNX	Annexon Inc	2020-07-28	2,730,635	4.83	13,188,967
CALC	CalciMedica Inc	2020-09-29	1,930,395	5.70	10,995,530
ETTX	Entasis Therapeutics Holdings Inc	2018-09-28	1,623,405	2.19	3,555,257
GRTS	Gritstone Bio Inc	2018-09-28	2,567,445	0.76	1,953,312
TALS	Talaris Therapeutics Inc	2021-05-11	503,577	2.72	1,369,729

Holding Weightings of Clarus Lifesciences Iii, L.p.

Clarus Lifesciences Iii, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Clarus Lifesciences Iii, L.p. has made a total of 0 transactions in Forty Seven Inc (FTSV) over the past 5 years. The most-recent trade in Forty Seven Inc is the acquisition of 200,000 shares on July 2, 2018, which cost Clarus Lifesciences Iii, L.p. around $3 Million.

According to the SEC Form 4 filings, Clarus Lifesciences Iii, L.p. has made a total of 1 transactions in Imago BioSciences Inc (IMGO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Imago BioSciences Inc is the acquisition of 150,000 shares on July 20, 2021, which cost Clarus Lifesciences Iii, L.p. around $2 Million.

According to the SEC Form 4 filings, Clarus Lifesciences Iii, L.p. has made a total of 1 transactions in Annexon Inc (ANNX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Annexon Inc is the acquisition of 200,000 shares on July 28, 2020, which cost Clarus Lifesciences Iii, L.p. around $3 Million.

More details on Clarus Lifesciences Iii, L.p.'s insider transactions can be found in the Insider Trading History of Clarus Lifesciences Iii, L.p. table.

Insider Trading History of Clarus Lifesciences Iii, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Clarus Lifesciences Iii, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Clarus Lifesciences Iii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Clarus Lifesciences Iii, L.p. is 18.18%. GuruFocus also compares Clarus Lifesciences Iii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Clarus Lifesciences Iii, L.p. within 3 months outperforms 4 times out of 7 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Clarus Lifesciences Iii, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Clarus Lifesciences Iii, L.p.

Average Return

Average return per transaction

Outperforming Transactions

2 out of 7 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	8.13
Relative Return to S&P 500(%)	8.21

Clarus Lifesciences Iii, L.p. Ownership Network

Ownership Network List of Clarus Lifesciences Iii, L.p.

No Data

Ownership Network Relation of Clarus Lifesciences Iii, L.p.

Clarus Lifesciences Iii, L.p. Owned Company Details

What does Praxis Precision Medicines Inc do?

Who are the key executives at Praxis Precision Medicines Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of Praxis Precision Medicines Inc. Other key executives at Praxis Precision Medicines Inc include Chief Executive Officer Marcio Souza , Chief Financial Officer Timothy Edwin Kelly , and Principal Accounting Officer Lauren Mastrocola .

Praxis Precision Medicines Inc (PRAX) Insider Trades Summary

Over the past 18 months, Clarus Lifesciences Iii, L.p. made no insider transaction in Praxis Precision Medicines Inc (PRAX). Other recent insider transactions involving Praxis Precision Medicines Inc (PRAX) include a net purchase of 80,002 shares made by Marcio Souza , a net purchase of 50,000 shares made by Dean J Mitchell , and a net purchase of 14,500 shares made by Jill Desimone .

In summary, during the past 3 months, insiders sold 0 shares of Praxis Precision Medicines Inc (PRAX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Praxis Precision Medicines Inc (PRAX) were sold and 10,167 shares were bought by its insiders, resulting in a net purchase of 10,167 shares.

Praxis Precision Medicines Inc (PRAX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Praxis Precision Medicines Inc Insider Transactions

No Available Data

What does ESSA Pharma Inc do?

Who are the key executives at ESSA Pharma Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of ESSA Pharma Inc. Other key executives at ESSA Pharma Inc include Chief Operating Officer Peter Virsik , director & Chief Executive Officer David Ross Parkinson , and Chief Financial Officer David S. Wood .

ESSA Pharma Inc (EPIX) Insider Trades Summary

Over the past 18 months, Clarus Lifesciences Iii, L.p. made no insider transaction in ESSA Pharma Inc (EPIX). Other recent insider transactions involving ESSA Pharma Inc (EPIX) include a net sale of 78,475 shares made by Peter Virsik , a net purchase of 99,730 shares made by Franklin M Berger , and a net purchase of 33,657 shares made by David Ross Parkinson .

In summary, during the past 3 months, insiders sold 2,082 shares of ESSA Pharma Inc (EPIX) in total and bought 0 shares, with a net sale of 2,082 shares. During the past 18 months, 78,475 shares of ESSA Pharma Inc (EPIX) were sold and 133,387 shares were bought by its insiders, resulting in a net purchase of 54,912 shares.

ESSA Pharma Inc (EPIX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ESSA Pharma Inc Insider Transactions

No Available Data

What does CalciMedica Inc do?

Who are the key executives at CalciMedica Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of CalciMedica Inc. Other key executives at CalciMedica Inc include director & 10 percent owner & Chief Business Officer Eric W Roberts , 10 percent owner Sanderling Venture Partners Vi Co Investment Fund Lp , and director & 10 percent owner Fred A Middleton .

CalciMedica Inc (CALC) Insider Trades Summary

Over the past 18 months, Clarus Lifesciences Iii, L.p. made no insider transaction in CalciMedica Inc (CALC). Other recent insider transactions involving CalciMedica Inc (CALC) include a net purchase of 65,404 shares made by Eric W Roberts , a net purchase of 20,768 shares made by A. Rachel Leheny , and a net purchase of 691,098 shares made by Fred A Middleton .

In summary, during the past 3 months, insiders sold 0 shares of CalciMedica Inc (CALC) in total and bought 4,000 shares, with a net purchase of 4,000 shares. During the past 18 months, 0 shares of CalciMedica Inc (CALC) were sold and 1,505,415 shares were bought by its insiders, resulting in a net purchase of 1,505,415 shares.

CalciMedica Inc (CALC)'s detailed insider trading history can be found in Insider Trading Tracker table.

CalciMedica Inc Insider Transactions

No Available Data

What does Annexon Inc do?

Who are the key executives at Annexon Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of Annexon Inc. Other key executives at Annexon Inc include EVP & Chief Innovation Officer Ted Yednock , EVP & Chief Business Officer Michael Overdorf , and EVP & Chief Financial Officer Jennifer Lew .

Annexon Inc (ANNX) Insider Trades Summary

Over the past 18 months, Clarus Lifesciences Iii, L.p. made no insider transaction in Annexon Inc (ANNX). Other recent insider transactions involving Annexon Inc (ANNX) include a net sale of 47,471 shares made by Ted Yednock , a net sale of 7,367 shares made by Jennifer Lew , and a net sale of 5,923 shares made by Michael Overdorf .

In summary, during the past 3 months, insiders sold 0 shares of Annexon Inc (ANNX) in total and bought 6,400 shares, with a net purchase of 6,400 shares. During the past 18 months, 73,114 shares of Annexon Inc (ANNX) were sold and 3,303,458 shares were bought by its insiders, resulting in a net purchase of 3,230,344 shares.

Annexon Inc (ANNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Annexon Inc Insider Transactions

No Available Data

What does Avrobio Inc do?

Who are the key executives at Avrobio Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of Avrobio Inc. Other key executives at Avrobio Inc include Chief Technology Officer Azadeh Golipour , Chief Medical Officer Essra Ridha , and Chief Scientific Officer Christopher Mason .

Avrobio Inc (AVRO) Insider Trades Summary

Over the past 18 months, Clarus Lifesciences Iii, L.p. made no insider transaction in Avrobio Inc (AVRO). Other recent insider transactions involving Avrobio Inc (AVRO) include a net purchase of 766,635 shares made by Braden Michael Leonard ,

In summary, during the past 3 months, insiders sold 0 shares of Avrobio Inc (AVRO) in total and bought 766,635 shares, with a net purchase of 766,635 shares. During the past 18 months, 0 shares of Avrobio Inc (AVRO) were sold and 766,635 shares were bought by its insiders, resulting in a net purchase of 766,635 shares.

Avrobio Inc (AVRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avrobio Inc Insider Transactions

No Available Data

What does Gritstone Bio Inc do?

Who are the key executives at Gritstone Bio Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of Gritstone Bio Inc. Other key executives at Gritstone Bio Inc include director & President and CEO Andrew R Allen , See Remarks Matthew Hawryluk , and See Remarks Karin Jooss .

Gritstone Bio Inc (GRTS) Insider Trades Summary

Over the past 18 months, Clarus Lifesciences Iii, L.p. made no insider transaction in Gritstone Bio Inc (GRTS). Other recent insider transactions involving Gritstone Bio Inc (GRTS) include a net sale of 1,749 shares made by Vassiliki Economides , a net sale of 24,263 shares made by Andrew R Allen , and a net sale of 13,749 shares made by Erin Jones .

In summary, during the past 3 months, insiders sold 74,769 shares of Gritstone Bio Inc (GRTS) in total and bought 0 shares, with a net sale of 74,769 shares. During the past 18 months, 74,769 shares of Gritstone Bio Inc (GRTS) were sold and 12,000 shares were bought by its insiders, resulting in a net sale of 62,769 shares.

Gritstone Bio Inc (GRTS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gritstone Bio Inc Insider Transactions

No Available Data

What does Entasis Therapeutics Holdings Inc do?

Who are the key executives at Entasis Therapeutics Holdings Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of Entasis Therapeutics Holdings Inc. Other key executives at Entasis Therapeutics Holdings Inc include 10 percent owner Theravance Inc , VP & Principal Fin & Acct Off Kristie Ann Wagner , and Chief Medical Officer David Altarac .

Entasis Therapeutics Holdings Inc (ETTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Entasis Therapeutics Holdings Inc (ETTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Entasis Therapeutics Holdings Inc (ETTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Entasis Therapeutics Holdings Inc (ETTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Entasis Therapeutics Holdings Inc Insider Transactions

No Available Data

What does Forty Seven Inc do?

Who are the key executives at Forty Seven Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of Forty Seven Inc. Other key executives at Forty Seven Inc include Chief Financial Officer Ann D Rhoads , 10 percent owner Lightspeed General Partner X, L.p. , and 10 percent owner Lightspeed Ultimate General Partner X, Ltd. .

Forty Seven Inc (FTSV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Forty Seven Inc (FTSV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Forty Seven Inc (FTSV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Forty Seven Inc (FTSV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Forty Seven Inc Insider Transactions

No Available Data

What does Imago BioSciences Inc do?

Who are the key executives at Imago BioSciences Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of Imago BioSciences Inc. Other key executives at Imago BioSciences Inc include Chief Operating Officer Laura G. Eichorn , See Remarks Michael Arenberg , and director & Chief Executive Officer Hugh Jr Rienhoff .

Imago BioSciences Inc (IMGO) Insider Trades Summary

Over the past 18 months, Clarus Lifesciences Iii, L.p. made no insider transaction in Imago BioSciences Inc (IMGO). Other recent insider transactions involving Imago BioSciences Inc (IMGO) include a net sale of 238,844 shares made by Jennifer Peppe , a net sale of 129,814 shares made by Laura G. Eichorn , and a net sale of 118,258 shares made by Michael Arenberg .

In summary, during the past 3 months, insiders sold 0 shares of Imago BioSciences Inc (IMGO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,060,311 shares of Imago BioSciences Inc (IMGO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,060,311 shares.

Imago BioSciences Inc (IMGO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imago BioSciences Inc Insider Transactions

No Available Data

What does Talaris Therapeutics Inc do?

Who are the key executives at Talaris Therapeutics Inc?

Clarus Lifesciences Iii, L.p. is the 10 percent owner of Talaris Therapeutics Inc. Other key executives at Talaris Therapeutics Inc include Interim CFO Ryan F. Robinson , Chief Medical Officer Yung H. Chyung , and CBO & GC and Secretary W Bradford Middlekauff .

Talaris Therapeutics Inc (TALS) Insider Trades Summary

Over the past 18 months, Clarus Lifesciences Iii, L.p. made no insider transaction in Talaris Therapeutics Inc (TALS). Other recent insider transactions involving Talaris Therapeutics Inc (TALS) include a net sale of 505,845 shares made by Suzanne Ildstad ,

In summary, during the past 3 months, insiders sold 0 shares of Talaris Therapeutics Inc (TALS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 50,585 shares of Talaris Therapeutics Inc (TALS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 50,585 shares.

Talaris Therapeutics Inc (TALS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Talaris Therapeutics Inc Insider Transactions

No Available Data

Clarus Lifesciences Iii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Clarus Lifesciences Iii, L.p.. You might contact Clarus Lifesciences Iii, L.p. via mailing address: 101 Main Street, Suite 1210, Cambridge Ma 02142.

Discussions on Clarus Lifesciences Iii, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.